Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00313222




Registration number
NCT00313222
Ethics application status
Date submitted
10/04/2006
Date registered
12/04/2006
Date last updated
15/02/2010

Titles & IDs
Public title
Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
Scientific title
Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Secondary ID [1] 0 0
AC-052-366
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Thromboembolic Pulmonary Hypertension 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - bosentan

Treatment: Drugs: bosentan
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline to Week 16 in 6-Minute Walk Test distance
Timepoint [1] 0 0
Week 16
Primary outcome [2] 0 0
Change from Baseline to Week 16 in Pulmonary Vascular Resistance at rest
Timepoint [2] 0 0
Week 16
Secondary outcome [1] 0 0
Change from Baseline to Week 16 in modified NYHA functional class
Timepoint [1] 0 0
Week 16
Secondary outcome [2] 0 0
Time to clinical worsening
Timepoint [2] 0 0
Time to clinical worsening

Eligibility
Key inclusion criteria
- Symptomatic pulmonary hypertension in modified NYHA functional class II to IV due to
CTEPH as demonstrated by ventilation/perfusion lung scanning and pulmonary
angiography.

- CTEPH judged inoperable because of peripheral localization of thrombotic material or
persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (PEA)
with no evidence of recurrent thromboembolism and not amenable to repeated surgery.

- 6-minute walk test (6MWT) distance < 450 m.

- Hemodynamic evaluation showing: Mean pulmonary arterial pressure (mPAP) >= 25 mmHg;
Pulmonary capillary wedge pressure (PCWP) < 15 mmHg; Pulmonary vascular resistance
(PVR) at rest >= 300 dyn×sec/cm5

- For patients who underwent PEA, hemodynamic evaluation must have been performed more
than 6 months after PEA.

- For all patients, hemodynamic evaluation must have been performed with the 3 months
immediately preceding inclusion.

- Men or women >= 18 and =< 80 years of age (Women of childbearing potential must have a
negative pre-treatment pregnancy test and use a reliable method of contraception).

- Anticoagulants at efficacious dose for at least 3 months prior to randomization.

- Signed informed consent prior to initiation of any study-mandated procedure.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Other forms of pulmonary hypertension including pulmonary hypertension related to
sickle cell disease.

- Obstructive lung disease: FEV1/FVC < 0.5 after bronchodilator.

- Severe restrictive lung disease: Total Lung Capacity < 60% of predicted value.

- Acute or chronic impairment (other than dyspnea), limiting the ability to comply with
study requirements (in particular with 6MWT), e.g., angina pectoris, intermittent
claudication.

- Symptomatic pulmonary embolism within 6 months prior to randomization.

- Pulmonary endarterectomy within 6 months prior to randomization.

- Psychotic, addictive or other disorder limiting the ability to provide informed
consent or to comply with study requirements.

- Illness with a life expectancy of less than 6 months.

- Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.

- AST and/or ALT > 3 times the upper limit of normal ranges.· Hemoglobin concentration <
75% the lower limit of normal ranges.

- Pregnancy or breast-feeding.

- Systolic blood pressure (BP) < 85 mmHg.

- Treatment or planned treatment with another investigational drug and/or pulmonary
angioplasty within 3 months prior to randomization.

- Treatment with an endothelin receptor antagonist, a phosphodiesterase inhibitor,
L-arginine or with prostanoids (excluding acute administration during a
catheterization procedure to test vascular reactivity) within 3 months prior to
randomization.

- Treatment for pulmonary hypertension within 1 month prior to randomization, excluding
calcium channel blockers if present for at least 1 month before randomization.

- Treatment with calcineurin-inhibitors (e.g., cyclosporine A and tacrolimus),
sirolimus, fluconazole, glibenclamide (glyburide) within 1 week prior to
randomization.

- Known hypersensitivity to bosentan or any of the excipients.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2007
Sample size
Target
Accrual to date
Final
157
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
St. Vincent's Hospital - Darlinghurst
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [3] 0 0
Royal Perth Hospital - Perth
Recruitment hospital [4] 0 0
The Prince Charles Hospital - Brisbane
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
6000 - Perth
Recruitment postcode(s) [4] 0 0
4032 - Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Minnesota
Country [3] 0 0
United States of America
State/province [3] 0 0
North Carolina
Country [4] 0 0
Austria
State/province [4] 0 0
Vienna
Country [5] 0 0
Belgium
State/province [5] 0 0
Brussels
Country [6] 0 0
Belgium
State/province [6] 0 0
Leuven
Country [7] 0 0
Canada
State/province [7] 0 0
British Columbia
Country [8] 0 0
Canada
State/province [8] 0 0
Ontario
Country [9] 0 0
Canada
State/province [9] 0 0
Quebec
Country [10] 0 0
Czech Republic
State/province [10] 0 0
Praha 2
Country [11] 0 0
France
State/province [11] 0 0
Bron Cedex
Country [12] 0 0
France
State/province [12] 0 0
Clamart
Country [13] 0 0
Germany
State/province [13] 0 0
Giessen
Country [14] 0 0
Germany
State/province [14] 0 0
Hannover
Country [15] 0 0
Germany
State/province [15] 0 0
Mainz
Country [16] 0 0
Italy
State/province [16] 0 0
Bologna
Country [17] 0 0
Italy
State/province [17] 0 0
Orbassano
Country [18] 0 0
Italy
State/province [18] 0 0
Pavia
Country [19] 0 0
Italy
State/province [19] 0 0
Trieste
Country [20] 0 0
Netherlands
State/province [20] 0 0
Amsterdam
Country [21] 0 0
Netherlands
State/province [21] 0 0
Nieuwegein
Country [22] 0 0
Poland
State/province [22] 0 0
Warszawa
Country [23] 0 0
Spain
State/province [23] 0 0
Barcelona
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Cambridge
Country [25] 0 0
United Kingdom
State/province [25] 0 0
Glasgow

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Actelion
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The present trial investigates a possible use of oral bosentan, which is currently approved
for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering
from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) because of (i)
peripheral localization of thrombotic material or (ii) persistent or recurrent pulmonary
hypertension after pulmonary endarterectomy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00313222
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00313222